These compounds may interact with:
Cytochrome P450 1A2
Potentially involved in: cardiovascular system disease; substance-related disorder; carcinoma; cancer; porphyria cutanea tarda; schizophrenia; liver disease; autoimmune hepatitis; amelogenesis imperfecta type 1b; autoimmune polyendocrine syndrome; squamous cell carcinoma; colorectal neoplasms; diabetes mellitus, non-insulin-dependent; growth disorders; hepatomegaly; liver cirrhosis, experimental; liver diseases; liver neoplasms, experimental; chronic obstructive airway disease; lung neoplasms
Disease data sourced from Pharos.